Celularity (CELU) Competitors $2.11 -0.05 (-2.31%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.19 +0.08 (+3.74%) As of 07/11/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELU vs. IPHA, VTYX, DERM, PBYI, DMAC, SPRO, ALMS, DRUG, VYGR, and ELDNShould you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Innate Pharma (IPHA), Ventyx Biosciences (VTYX), Journey Medical (DERM), Puma Biotechnology (PBYI), DiaMedica Therapeutics (DMAC), Spero Therapeutics (SPRO), Alumis (ALMS), Bright Minds Biosciences (DRUG), Voyager Therapeutics (VYGR), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. Celularity vs. Its Competitors Innate Pharma Ventyx Biosciences Journey Medical Puma Biotechnology DiaMedica Therapeutics Spero Therapeutics Alumis Bright Minds Biosciences Voyager Therapeutics Eledon Pharmaceuticals Innate Pharma (NASDAQ:IPHA) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk. Which has more volatility & risk, IPHA or CELU? Innate Pharma has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Is IPHA or CELU more profitable? Innate Pharma has a net margin of 0.00% compared to Celularity's net margin of -106.77%. Innate Pharma's return on equity of 0.00% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Innate PharmaN/A N/A N/A Celularity -106.77%-271.88%-42.82% Does the media refer more to IPHA or CELU? In the previous week, Celularity had 2 more articles in the media than Innate Pharma. MarketBeat recorded 3 mentions for Celularity and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.89 beat Celularity's score of 0.63 indicating that Innate Pharma is being referred to more favorably in the media. Company Overall Sentiment Innate Pharma Very Positive Celularity Positive Do insiders & institutionals believe in IPHA or CELU? 0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 22.1% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings & valuation, IPHA or CELU? Innate Pharma has higher earnings, but lower revenue than Celularity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnate Pharma$21.77M7.38-$53.53MN/AN/ACelularity$54.22M0.93-$57.89M-$2.65-0.80 Do analysts prefer IPHA or CELU? Innate Pharma currently has a consensus target price of $11.00, indicating a potential upside of 531.02%. Given Innate Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Innate Pharma is more favorable than Celularity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Celularity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryInnate Pharma beats Celularity on 11 of the 15 factors compared between the two stocks. Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELU vs. The Competition Export to ExcelMetricCelularityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.53M$2.94B$5.56B$9.10BDividend YieldN/A2.41%5.06%4.02%P/E Ratio-0.8020.8528.2620.26Price / Sales0.93262.20427.10161.28Price / CashN/A42.1137.1257.67Price / Book5.707.638.045.49Net Income-$57.89M-$55.05M$3.19B$250.45M7 Day Performance2.93%8.43%3.62%4.79%1 Month Performance20.57%8.14%5.98%9.59%1 Year Performance-28.47%1.62%29.39%16.41% Celularity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELUCelularity0.0944 of 5 stars$2.11-2.3%N/A-28.5%$50.53M$54.22M-0.80220News CoverageUpcoming EarningsIPHAInnate Pharma2.6291 of 5 stars$1.82-1.9%$11.00+506.1%-21.7%$170.53M$21.77M0.00220Positive NewsGap DownVTYXVentyx Biosciences3.5147 of 5 stars$2.14-8.5%$10.00+367.3%+7.0%$166.52MN/A-1.2230News CoveragePositive NewsDERMJourney Medical1.9791 of 5 stars$7.18+0.6%$9.50+32.3%+26.3%$166.33M$56.13M-18.4190PBYIPuma Biotechnology4.2264 of 5 stars$3.43+3.0%$7.00+104.1%-5.6%$165.27M$230.50M4.45200Trending NewsDMACDiaMedica Therapeutics1.1902 of 5 stars$3.90+1.6%$8.00+105.1%+4.6%$164.67MN/A-6.0920SPROSpero Therapeutics3.9703 of 5 stars$2.90-1.4%$5.00+72.4%+98.6%$164.38M$47.98M-2.27150Positive NewsALMSAlumis3.5967 of 5 stars$3.00-0.7%$22.86+661.9%-68.3%$164.30MN/A0.00N/APositive NewsDRUGBright Minds Biosciences2.0992 of 5 stars$26.11+12.2%$83.25+218.8%+2,477.7%$163.91MN/A-72.53N/AVYGRVoyager Therapeutics3.977 of 5 stars$3.11+5.1%$13.39+330.5%-60.2%$163.80M$80M-2.13100High Trading VolumeELDNEledon Pharmaceuticals1.5156 of 5 stars$2.71+0.7%$9.00+232.1%+34.6%$161.08MN/A-1.2910Analyst Revision Related Companies and Tools Related Companies IPHA Competitors VTYX Competitors DERM Competitors PBYI Competitors DMAC Competitors SPRO Competitors ALMS Competitors DRUG Competitors VYGR Competitors ELDN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELU) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
